CVE-2023-37613 — MEDIUM (6.1)

Vulnerability Description

A cross-site scripting (XSS) vulnerability in Assembly Software Trialworks v11.4 allows attackers to execute arbitrary web scripts or HTML via injecting a crafted payload into the asset src parameter.

CVSS Score

6.1

MEDIUM

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Attack Vector

NETWORK

Attack Complexity

LOW

Privileges Required

NONE

User Interaction

REQUIRED

Scope

CHANGED

Confidentiality

LOW

Integrity

LOW

Availability

NONE

Affected Products

Vendor	Product	Versions
Assemblysoftware	Trialworks	11.4

Related Weaknesses (CWE)

CWE-79

References

https://github.com/HeidiSecurities/CVEs/blob/main/CVE-2023-37613/Trialworks.mdExploitThird Party Advisory
https://github.com/HeidiSecurities/CVEs/blob/main/Trialworks.mdBroken Link
https://github.com/HeidiSecurities/CVEs/blob/main/CVE-2023-37613/Trialworks.mdExploitThird Party Advisory
https://github.com/HeidiSecurities/CVEs/blob/main/Trialworks.mdBroken Link

FAQ

What is CVE-2023-37613?

CVE-2023-37613 is a vulnerability with a CVSS score of 6.1 (MEDIUM). A cross-site scripting (XSS) vulnerability in Assembly Software Trialworks v11.4 allows attackers to execute arbitrary web scripts or HTML via injecting a crafted payload into the asset src parameter.

How severe is CVE-2023-37613?

CVE-2023-37613 has been rated MEDIUM with a CVSS base score of 6.1/10. Review the CVSS metrics above for detailed severity breakdown.

Is there a patch for CVE-2023-37613?

Check the references section above for vendor advisories and patch information. Affected products include: Assemblysoftware Trialworks.